Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Clin Epidemiol ; 66(1): 36-43, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23177893

RESUMO

OBJECTIVE: To study the seroepidemiology and antimicrobial resistance pattern of invasive pneumococcal disease (IPD) in older subjects who are admitted to hospitals in India. STUDY DESIGN AND SETTING: Prospective surveillance of IPD in patients older than 18 years in seven large academic teaching hospitals in India from 1993 to 2008. All subjects who had Streptococcus pneumoniae isolated from normally sterile body fluids or were antigen positive in cerebrospinal fluid, ascitic fluid, and pleural fluid were identified as IPD cases in the study. Serotype/group (STG) and minimum inhibitory concentration for penicillin, chloramphenicol, co-trimoxazole (trimethoprim-sulfamethoxazole), erythromycin, and cefotaxime were determined. RESULTS: A total of 1,037 adult subjects with suspected invasive bacterial infection were recruited in the study. S pneumoniae was identified from normally sterile body fluids in 449 (43.3%) subjects. Meningitis (34.3%) and pneumonia (33.9%) were the most common clinical conditions associated with IPD. The case fatality was 25-30% across all age groups. Penicillin resistance was low at 2.7% overall. Resistance to co-trimoxazole was noted to be high and increasing in the study period from 42.9% in 1993 to 85.2% in 2008 (P = 0.001). The most common STG was serotype 1, which accounted for 22.9% of all isolates. The 23-valent pneumococcal polysaccharide vaccine covered 83.3% of the STGs (49/54; 95% confidence interval: 79.7, 96.9) for patients older than 60 years. CONCLUSION: IPD continues to be a problem in India and is associated with high case fatality in spite of treatment in the hospital setting. Penicillin resistance is currently low in India. More than 80% of invasive STGs causing disease in the elderly in India are included in the formulation of polysaccharide pneumococcal vaccine.


Assuntos
Infecções Pneumocócicas/mortalidade , Antibacterianos/uso terapêutico , Farmacorresistência Bacteriana Múltipla , Feminino , Humanos , Índia/epidemiologia , Masculino , Meningite Pneumocócica/tratamento farmacológico , Meningite Pneumocócica/epidemiologia , Meningite Pneumocócica/microbiologia , Meningite Pneumocócica/mortalidade , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Infecções Pneumocócicas/tratamento farmacológico , Infecções Pneumocócicas/epidemiologia , Infecções Pneumocócicas/microbiologia , Pneumonia Pneumocócica/tratamento farmacológico , Pneumonia Pneumocócica/epidemiologia , Pneumonia Pneumocócica/microbiologia , Pneumonia Pneumocócica/mortalidade , Estudos Prospectivos , Streptococcus pneumoniae/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...